KYMR
Kymera Therapeutics Inc
NASDAQ: KYMR · HEALTHCARE · BIOTECHNOLOGY
$81.51
-2.79% today
Updated 2026-04-29
Market cap
$6.65B
P/E ratio
—
P/S ratio
169.71x
EPS (TTM)
$-3.69
Dividend yield
—
52W range
$28 – $103
Volume
0.7M
Kymera Therapeutics Inc (KYMR) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-17.86M | $17.91M | $88.13M | $-128.95M | $-153.09M | $-102.83M | $-194.50M | $-232.89M |
| Capital expenditures | $1.36M | $532000.00 | $9.10M | $1.60M | $2.84M | $34.48M | $12.84M | $1.45M |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | $648000.00 | $1.20M | $5.19M | $24.97M | $35.48M | $43.12M | $55.01M | $59.90M |
| Free cash flow | $-19.22M | $17.37M | $79.03M | $-130.54M | $-155.92M | $-137.31M | $-207.34M | $-234.34M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $-45.20M | $21.50M | $20.43M | — | — | — |